Latest Biotech Startup Funding Rounds
Financing for drug discovery, therapeutics and biological technologies, with the development context behind each round.
- Rounds
- 470 Jan 1 – Oct 24, 2026
- Disclosed funding
- $19.5B 399 disclosed amounts
- Median round
- $20M Of disclosed amounts
| Company | Amount | Round | Sector | Country | Investors | Announced |
|---|---|---|---|---|---|---|
| S SkinBitCompany profile Provides full-body skin scanning technology for early skin cancer detection and screening Provides full-body skin scanning technology for early skin cancer detection and screening | $6M | Pre-SeedPre-seed | Biotech, Healthtech | United States | Investors | |
| M MironidCompany profile Mironid develops small-molecule medicines for inherited kidney disease, with a lead programme targeting autosomal dominant polycystic kidney disease. Mironid develops small-molecule medicines for inherited kidney disease, with a lead programme targeting autosomal dominant polycystic kidney disease. | $46M | Series B | Biotech | United Kingdom | Investors | |
| LT LifeMine TherapeuticsCompany profile Develops fungal genome-derived therapeutics for organ transplant rejection Develops fungal genome-derived therapeutics for organ transplant rejection | $263M | Series D+Series EUndisclosed | Biotech | United States | Investors | |
| VB Vedanta BiosciencesCompany profile Develops microbiome-based oral therapies for prevention of recurrent C. difficile infection Develops microbiome-based oral therapies for prevention of recurrent C. difficile infection | $60M | Growth | Biotech | United States | Investors | |
| Q QuantHealthCompany profile AI-driven platform that simulates clinical trials to predict outcomes before patient enrollment AI-driven platform that simulates clinical trials to predict outcomes before patient enrollment | $45M | Series B | Biotech | Israel | Investors | |
| CL CND Life SciencesCompany profile Develops biomarker-based diagnostic tests for neurodegenerative diseases Develops biomarker-based diagnostic tests for neurodegenerative diseases | Undisclosed | Growth | Biotech | United States | Investors | |
| C Uses genomic surveillance to identify hospital infection outbreaks and sources | $3.5M | Pre-SeedPre-seed | Biotech | United States | Investors | |
| I Whole-genome sequencing and bioinformatics platform for precision oncology | $31M | Series B | Biotech | United States | Investors | |
| DB Dash BioCompany profile Dash Bio provides automated bioanalysis for preclinical and clinical drug testing. Dash Bio provides automated bioanalysis for preclinical and clinical drug testing. | $30M | Series A | Biotech | United States | Investors | |
| RT Developing best-in-class radiopharmaceuticals for cancer treatment | $70M | Series CSeries C+ | Biotech | United States | Investors |
Active investors in this selection
All investors →Ranked by rounds participated in · From Jan 1, 2026
- 1RA Capital Management
Estuary Biotherapeutics, Circle Pharma, Inc., Solstice Oncology
22rounds3led - 2Janus Henderson Investors
Star Therapeutics, OMass Therapeutics, Soufflé Therapeutics
15rounds1led - 3Eli Lilly and Company
BigHat Biosciences, Circle Pharma, Inc., Moonwalk Biosciences
15rounds0led - 4ARCH Venture Partners
Soufflé Therapeutics, Encoded Therapeutics Inc., Moonwalk Biosciences
14rounds0led - 5OrbiMed
Star Therapeutics, Leal Therapeutics, Accro Bioscience
11rounds1led
Latest digests
Archive →Explore published rounds while the next edition is being prepared.